{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"tb-500-glp1-agonists","urls":{"read":"https://miscsubjects.com/api/articles/tb-500-glp1-agonists/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/tb-500-glp1-agonists/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/tb-500-glp1-agonists/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/tb-500-glp1-agonists/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/tb-500-glp1-agonists/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/tb-500-glp1-agonists/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/tb-500-glp1-agonists/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"tb-500-glp1-agonists","title":"tb 500 glp1 agonists","register":"standard","tags":["peptide"],"updated_at":"2026-07-17T02:42:14.788Z","body_excerpt":"## Regeneration vs degeneration — where this fits\n\nglp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether tb-500 mechanisms address underlying repair deficits.\n\n## What is known\n\nStudied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\n\nTarget condition: glp1 agonists.\nBody system: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss..\n\n## Logic chain\n\n1. tb-500 studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure..\n2. glp1 agonists involves metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. dysfunction.\n3. If tb-500 reaches the affected tissue, it may shift the repair/breakdown balance.\n4. This chain is tested in animal or lab models only.\n\n## Parent peptide claims relevant here\n\n- Tβ4 promotes cell migration, angiogenesis, and modulates inflammation via actin sequestration.\n- Topical or systemic Tβ4 accelerates wound healing and re-epithelialization in rat full-thickness wound models.\n- Intravenous synthetic Tβ4 was well tolerated in Phase 1 single- and multiple-dose studies in healthy volunteers with no dose-limiting toxicity.\n- Topical Tβ4 accelerated healing by nearly one month in Phase 2 trials of stasis and pressure ulcers in some patients who healed.\n- Tβ4 production declines approximately 60% by age 60.\n\n## Evidence tier\n\nPreclinical — animal and in vitro studies only. No published human trials for this specific combination.\n\n## What we do not know\n\n- Whether tb-500 reaches glp1 agonists tissue at functional concentrations\n- Optimal dosing, route, and duration for this target\n- Interaction with standard-of-care treatments for glp1 agonists\n- Long-term safety profile in this population\n\n## Safety note\n\nAll peptide use for glp1 agonists is research-context only. Not medical advice. Consult a physician before any experimental compound.","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c_map_tb-500-glp1-agonists","text":"Combinatorial mapping (transparent): tb-500 vs glp1-agonists — regen=0.41, degen=0.35, Δ=0.06. Method: layer_relevance(0.60) × evidence_factor(0.55); catalog.degen_score for GLP-1 agonists (class).","tier":"system","weight":0.35,"section":"what_is_known","interaction_risk":false,"status":"active","source_ids":[],"retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.35,"quote_gated":false}],"sources":[],"anecdotal_sources":[],"scientific_sources":[],"user_reports":[],"related_articles":[],"question_graph":{"slug":"tb-500-glp1-agonists","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":1,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":1,"claims_total":1,"sources":0,"anecdotal":0,"scientific":0,"user_reports":0,"questions":0,"evidence_ingests":0}}